Insider Trading March 12, 2026

Doximity Interim Finance Chief Sells $63,622 in Stock; Converts and Exercises Additional Shares

Sitaram Siddharth executed an automated sale under a 10b5-1 plan while converting Class B shares and exercising options amid mixed analyst assessments

By Derek Hwang DOCS
Doximity Interim Finance Chief Sells $63,622 in Stock; Converts and Exercises Additional Shares
DOCS

Interim Principal Financial Officer and Principal Accounting Officer Sitaram Siddharth sold a block of Doximity Class A shares on February 10, 2026 through an automated Rule 10b5-1 plan, while also converting Class B shares to Class A and exercising employee stock options. The transactions coincide with a material share price decline over the prior six months and a range of analyst reactions following the company’s fiscal third-quarter beat on revenue and EBITDA.

Key Points

  • Sitaram Siddharth sold 2,282 Class A shares on February 10, 2026 at $27.88 per share for $63,622 under a Rule 10b5-1 trading plan; he also converted 5,000 Class B shares to Class A and exercised 5,000 options at $4.12 each.
  • Doximity’s stock has fallen 65.82% over the past six months and was trading at $24.28 at the time of the report, near a 52-week low of $23.53.
  • Following fiscal third-quarter results that beat guidance and consensus on revenue and EBITDA by $4.6 million and $7.9 million respectively, analysts issued mixed guidance and ratings changes reflecting concerns about near-term headwinds, pharmaceutical marketing spend timing and AI disruption.

Interim Principal Financial Officer and Principal Accounting Officer Sitaram Siddharth sold 2,282 shares of Doximity, Inc. (NASDAQ: DOCS) Class A Common Stock on February 10, 2026 at $27.88 per share, for total proceeds of $63,622. The sale was processed automatically under a Rule 10b5-1 trading plan.

On the same date, Siddharth converted 5,000 shares of Class B Common Stock into Class A Common Stock. In addition, he acquired 5,000 shares through the exercise of stock options that carried an exercise price of $4.12 per share.

The sale took place while Doximity’s shares were trading at $24.28, below the sale price and close to the company’s 52-week low of $23.53. Over the past six months the stock has fallen 65.82%.

Despite the price decline, InvestingPro analysis included in available reporting indicates the shares may be undervalued at current levels. The company’s financial profile shows a gross profit margin of 89.75% and a price-to-earnings ratio of 20.51.


Market reaction and analyst positioning have been varied following Doximity’s fiscal third-quarter results. The company reported revenue and EBITDA that exceeded guidance and consensus estimates by $4.6 million and $7.9 million, respectively.

Several brokerages have updated their views in response to the quarter. BMO Capital lowered its price target on Doximity to $25 and maintained a Market Perform rating, citing near-term headwinds. Canaccord Genuity moved its rating from Hold to Buy while setting a reduced price target of $34, noting valuation concerns but attributing the recent selloff to perceived overreactions around pharmaceutical marketing budgets and disruption from AI. Mizuho also adjusted its price target to $34 while keeping a Neutral rating, pointing to delays in pharmaceutical marketing expenditures. Piper Sandler raised its price target to $42 and retained an Overweight rating after reviewing the company’s AI tool suite.

These analyst moves underscore divergent assessments of Doximity’s near-term challenges and longer-term prospects. The company’s recent financial beats contrast with concerns over marketing spend timing, valuation and the potential impact of AI-related shifts cited by analysts. At the current trading level noted above, insider activity included both divestiture under an automated plan and internal share-class conversion and option exercises by a senior finance executive.


Readers should note the specific, documented transactions and analyst commentary reported here. No additional assumptions about causation or future performance are made beyond the disclosed facts of the trades, conversions, option exercise and published analyst actions.

Risks

  • Near-term headwinds cited by BMO Capital could pressure the company’s performance and impact investor sentiment - this affects equity investors in healthcare technology and telehealth services.
  • Delays in pharmaceutical marketing expenditures, noted by Mizuho and others, present uncertainty for revenue growth tied to pharma clients - this impacts the healthcare marketing and advertising segment.
  • Valuation concerns and market overreactions related to AI disruption and pharma budgets, referenced by Canaccord Genuity, create potential volatility for shareholders and trading liquidity in the stock.

More from Insider Trading

Palladyne AI CFO Disposes $57,749 in Stock; Company Posts Strong Revenue Growth but Remains Loss-Making Mar 12, 2026 Palladyne AI Chief Legal Officer Disposes $51,355 in Stock; Executive Also Receives RSUs Mar 12, 2026 Palladyne AI CTO Disposes $97.7K in Stock as Shares Remain Volatile Mar 12, 2026 Figure Technology Director Disposes $7.29M in Class A Shares Mar 12, 2026 Stewart Information Director Adds 1,000 Shares in Mid-March Trades Mar 12, 2026